Neuroleptic malignant syndrome due to three atypical antipsychotics in a child

Journal of Psychopharmacology

Volumn 19, Issue 4, 2005, Pages 422-425

  Chungh, Dong Seon ^a   Kim, Boong Nyun ^b   Cho, Soo Churl ^a,b  

^a Seoul National University Bundang Hospital   (South Korea)

^b Seoul National University Hospital   (South Korea)

Author keywords

Neuroleptic malignant syndrome; Olanzapine; Quetiapine; Risperidone

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CARBAMAZEPINE; LITHIUM; METHYLPHENIDATE; OLANZAPINE; PARACETAMOL; QUETIAPINE; RISPERIDONE; VALPROIC ACID;

AGGRESSION; ARTICLE; ATTENTION DEFICIT DISORDER; AUTONOMIC DYSFUNCTION; BIPOLAR DISORDER; BODY TEMPERATURE; CASE REPORT; CLINICAL FEATURE; CONSCIOUSNESS DISORDER; DRUG ERUPTION; DRUG FATALITY; DRUG POTENCY; ELECTROCONVULSIVE THERAPY; FEMALE; HUMAN; HYPOTENSION; KIDNEY FAILURE; LETHARGY; MUSCLE RIGIDITY; MYALGIA; NEUROLEPTIC MALIGNANT SYNDROME; PHARYNGITIS; PRIORITY JOURNAL; RARE DISEASE; RESPIRATORY FAILURE; SCHOOL CHILD; STUPOR; TACHYCARDIA; TACHYPNEA; VIOLENCE;

AGGRESSION; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BIPOLAR DISORDER; BODY TEMPERATURE; CHILD; DIBENZOTHIAZEPINES; ELECTROCONVULSIVE THERAPY; FEMALE; HUMANS; IMPULSIVE BEHAVIOR; NEUROLEPTIC MALIGNANT SYNDROME; RISPERIDONE; VALPROIC ACID; VIOLENCE;

EID: 22344452618     PISSN: 02698811     EISSN: None     Source Type: Journal    
DOI: 10.1177/0269881105053310     Document Type: Article

References (34)

1. Aboraya A, Schumacher J, Abdalla E, Lepage J, McGhee M, Butcher D, Griffin H, Shahda M (2002) Neuroleptic malignant syndrome associated with risperidone and olanzapine in first-episode schizophrenia. W V Med J 98: 63-65
2. Addonizio G, Susman V L (1987) ECT as a treatment alternative for patients with symptoms of neuroleptic malignant syndrome. J Clin Psychiatry 48: 102-105
3. Bajjoka I, Patel T, O'Sullivan T (1997) Risperidone-induced neuroleptic malignant syndrome: a case report. Ann Emerg Med 30(5): 698-700
4. Beasley Jr, C M Tollfson G D, Tran P D (1997) Efficacy of olanzapine: an overview of pivotal trials. J Clin Psychiatry 58 (Suppl. 10): 7-12
5. Bottlender R, Jager M, Hofschuster E, Dobmeier P, Moller H J (2002) Three episodes in one patient. Pharmacopsychiatry 35: 119-121
6. Bymaster F D, Colligaro D O, Flacone J F (1996) Radio receptor binding profile of the atypical antipsychotic olazapine. Neuropsychopharmacology 14: 87-96
7. Caroff S N, Mann S C (1988) Neuroleptic malignant syndrome. Psychopharmacol Bull 24: 24-29
8. Caroff S N, Mann S C (1993) Neuroleptic malignant syndrome. Psychiatr Ann 77: 185-202
9. Casey D E (1996) Seroquel: preclinical and clinical findings of a new atypical antipsychotic. Exp Opin Invest Drugs 5: 939-957
10. David M, Remy C (1998) Case report: possible neuroleptic malignant syndrome associated with olanzapine. J Clin Psychopharmacol 18(6): 485-486
11. Donna W, Steven E S, Joseph P (2000) Nonextrapyramidal side effects of novel antipsychotics. Curr Opin Psychiatry 13(1): 45-50
12. Filice G A, McDougall B C, Ercan-Fang N (1998) Neuroleptic malignant syndrome associated with olanzapine. Ann Pharmacother 32: 158-1159
13. Gram L F (2002) Neuroleptic malignant syndrome in the treatment with the new, atypical antipsychotic agents, risperidone and olanzapine. Ugeskr Laeger 162: 1914-1915
14. Gratz S S, Simpson G M (1994) Neuroleptic malignant syndrome. Diagnosis, epidemiology and treatment. CNS Drugs 2: 429-439
15. Hasan S, Buckley P (1998) Novel antipsychotics and the neuroleptic malignant syndrome: a review and critique. Am J Psychiatry 155: 1113-1116
16. Jibson M D, Tanson R (1998) New atypical antipsychotic medications. J Psychiat Res 32: 215-222
17. Kara gianis J L, Phillips L C, Hogan K P, Le Drew K K (1999) Clozapine-associated neuroleptic malignant syndrome: two new cases and a review of the literature. Ann Pharmacother 33: 623-630
18. Kellam AMP (1987) The neuroleptic malignant syndrome, so-called: a survey of the world literature. Br J Psychiatry 150: 752-759
19. Keyser D L, Rodnitzky R L (1991) Neuroleptic malignant syndrome in Parkinson's disease after withdrawal or duration of dopaminergic therapy. Arch Intern Med 14: 794-796
20. Knezevic W, Mastaglia F, Lefroy R (1984) Neuroleptic malignant syndrome. Med J Aust 140: 28-30
21. Latz S, McCracken J (1992) Neuroleptic malignant syndrome in children and adolescents: two case reports and a warning. J Child Adolesc Psychopharmacol 2: 123-129
22. Mills K C (1993) Serotonin toxicity: a comprehensive review of emergency medicine. Top Emerg Med 15: 54-73
23. Nopoulos D, Flaum M, Miller D D (1990) Atypical neuroleptic malignant syndrome with an atypical neuroleptic: clozapine induced neuroleptic malignant syndrome without rigidity. Ann Clin Psychiatr 2: 2251-2253
24. Pearlman C A (1986) Neuroleptic malignant syndrome. J Clin Psychopharmacol 6: 257-273
25. Robb A S, Chang W, Lee H K, Cook M S (2002) Risperidone-induced neuroleptic malignant syndrome in an adolescent [Case study]. J Child Adolesc Psychopharmacol 10: 327-330
26. Saller C F, Salama A I (1993) Seroquel: biochemical profile of a potential atypical antipsychotic. Psychopharmacology 112: 285-292
27. Shalev A, Muniz H (1986) The neuroleptic malignant syndrome: agent and last interaction. Acta Psychiatry Scand 73: 337-347
28. Stanley A K, Hunter J (2000) Possible neuroleptic malignant syndrome with quetiapine. Br J Psychiatry 176: 497
29. Steingard R, Khan A, Gonzalez A, Herzog D (1992) Neuroleptic malignant syndrome: review of experience with children and adolescents. J Child Adolesc Psychopharmacol 2: 183-198
30. Stewart F (2002) Pharmacology of atypical antipsychotics. Clin Neuropharmacol 25(3): 153-157
31. Tarshy D, Baldessarini R J, Tarazi F T (2002) Effects of newer antipsychotics on extrapyramidal function. CNS Drugs 16: 23-45
32. Tsai G, Crisostomo G, Rosenblatt M L, Stern T A (1995) Neuroleptic malignant syndrome associated with clozapine treatment. Ann Clin Psychiatry 7: 91-95
33. Vikram D, Jober R (2000) Quetiapine: a review of its safety in the management of schizophrenia. Drug Safety 23: 295-307
34. Webster P, Wijeratne C (1994) Risperidone-induced neuroleptic malignant syndrome [letter]. Lancet 344: 1228-1229